Urodynamic effects of oxybutynin and tolterodine in conscious and anesthetized rats under different cystometrographic conditions
Tóm tắt
Antimuscarinic agents are the most popular treatment for overactive bladder and their efficacy in man is well documented, producing decreased urinary frequency and an increase in bladder capacity. During cystometry in rats, however, the main effect reported after acute treatment with antimuscarinics is a decrease in peak micturition pressure together with little or no effect on bladder capacity. In the present experiments we studied the effects, in rats, of the two most widely used antimuscarinic drugs, namely oxybutynin and tolterodine, utilising several different cystometrographic conditions. The aim was to determine the experimental conditions required to reproduce the clinical pharmacological effects of antimuscarinic agents, as seen in humans, in particular their ability to increase bladder capacity. Intravenous or oral administration of tolterodine or oxybutynin in conscious rats utilized 1 day after catheter implantation and with saline infusion at constant rate of 0.1 ml/min, gave a dose-dependent decrease of micturition pressure (MP) with no significant change in bladder volume capacity (BVC). When the saline infusion rate into the bladder was decreased to 0.025 ml/min, the effect of oral oxybutynin was similar to that obtained with the higher infusion rate. Also, experiments were performed in rats in which bladders were infused with suramin (3 and 10 μM) in order to block the non-adrenergic, non-cholinergic component of bladder contraction. Under these conditions, oral administration of oxybutynin significantly reduced MP (as observed previously), but again BVC was not significantly changed. In conscious rats with bladders infused with diluted acetic acid, both tolterodine and oxybutynin administered at the same doses as in animals infused with saline, reduced MP, although the reduction appeared less marked, with no effect on BVC. In conscious rats utilized 5 days after catheter implantation, a situation where inflammation due to surgery is reduced, the effect of tolterodine (i.v.) and oxybutynin (p.o.) on MP was smaller and similar, respectively, to that observed in rats utilized 1 day after catheter implantation, but the increase of BVC was not statistically significant. In anesthetized rats, i.v. administration of oxybutynin again induced a significant decrease in MP, although it was of questionable relevance. Both BVC and threshold pressure were not significantly reduced. The number and amplitude of high frequency oscillations in MP were unmodified by treatment. Finally, in conscious obstructed rats, intravenous oxybutynin did not modify frequency and amplitude of non-voiding contractions or bladder capacity and micturition volume. Despite the different experimental conditions used, the only effect on cystometrographic parameters of oxybutynin and tolterodine in anesthetized and conscious rats was a decrease in MP, whereas BVC was hardly and non-significantly affected. Therefore, it is difficult to reproduce in rats the cystometrographic increase in BVC as observed in humans after chronic administration of antimuscarinic agents, whereas the acute effects seem more similar.
Tài liệu tham khảo
Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, van Kerrebroeck P, Victor A, Wein A: The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Neurourol Urodyn. 2002, 21: 167-178. 10.1002/nau.10052.
Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ: How widespread are the symptoms of an overactive bladder and how are they managed ? A population-based prevalence study. BJU Int. 2001, 87: 760-766. 10.1046/j.1464-410x.2001.02228.x.
Wein AJ, Rovner ES: The overactive bladder: an overview for primary care health providers. Int J Fertil Womens Med. 1999, 44 (2): 56-66.
Brading AF: A myogenic basis for the overacting bladder. Urology. 1997, 50 (Suppl 6A): 57-67. 10.1016/S0090-4295(97)00591-8.
De Groat WC: A neurologic basis for the overactive bladder. Urology. 1997, 50 (Suppl 6A): 36-52. 10.1016/S0090-4295(97)00587-6.
Yoshimura N, Chancellor MB: Current and future pharmacological treatment for overactive bladder. J Urol. 2002, 168: 1897-1913. 10.1097/00005392-200211000-00004.
Chapple RC: Muscarinic receptor antagonists in the treatment of overactive bladder. Urology. 2000, 55 (Suppl 5A): 33-46. 10.1016/S0090-4295(99)00492-6.
Yarker YE, Goa KL, Fitton A: Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs & Aging. 1995, 6: 243-262.
Guarneri L, Cova R, Angelico P, Colli E, Testa R: Effects of different drugs on the cystometrogram in conscious rats. Pharmacol Res. 1991, 24: 175-187. 10.1016/1043-6618(91)90032-S.
Guarneri L, Ibba M, Angelico P, Testa R: Effects of oxybutynin, terodiline and nifedipine on the cystometrogram in conscious rats with infravesical outflow obstruction. Pharmacol Res. 1991, 24: 263-272. 10.1016/1043-6618(91)90090-K.
Yamamoto T, Koibuchi Y, Miura S, Sawada T, Ozaki R, Esumi K, Ohtsuka M: Effects of vamicamide on urinary bladder functions in conscious dog and rat models of urinary frequency. J Urol. 1995, 154: 2174-2178. 10.1097/00005392-199512000-00056.
Yokoyama O, Ishiura Y, Nakamura Y, Ohkawa M: Urodynamic effects of intravesical oxybutynin chloride in conscious rats. J Urol. 1996, 155: 768-771. 10.1097/00005392-199602000-00110.
Williamson IJR, Newgreen DT, Naylor AM: The effects of darifenacin and oxybutynin on bladder function and salivation in the conscious rat. Br J Pharmacol. 1997, 120: 205P-
Kwak TI, Lee JG: Inhibitory effects of propiverine, atropine and oxybutynin on bladder instability in rats with infravesical outlet obstruction. BJU. 1998, 82: 272-277. 10.1046/j.1464-410X.1998.00724.x.
Velasco C, Guarneri L, Leonardi A, Testa R: Influence of pump compliance (peristaltic vs. infusion) on urodynamic measurement during cystometry in conscious rats. J Pharmacol Toxicol Methods. 2001, 45: 215-21. 10.1016/S1056-8719(01)00151-4.
Modiri AR, Alberts P, Gillberg PG: Effect of muscarinic antagonists on micturition pressure measured by cystometry in normal, conscious rats. Urology. 2002, 59: 963-968. 10.1016/S0090-4295(02)01535-2.
Ishizuka O, Gu BJ, Yang ZX, Nishizawa O, Andersson K-E: Functional role of central muscarinic receptors for micturition in normal conscious rats. J Urol. 2002, 168: 2258-2262. 10.1097/00005392-200211000-00110.
Shimizu I, Kawashima K, Ishii D, Oka M: Urodynamics in a rat neurogenic bladder model with a unilateral electrolytic lesion of the basal forebrain. BJU Int. 2003, 91: 861-867. 10.1046/j.1464-410X.2003.04234.x.
Morrison J, Steers WD, Brading A, Blok B, Fry C, De Groat WC, Kakizaki H, Levin R, Thor K: Neurophysiology and neuropharmacology. Incontinence. Edited by: Abrams P, Cardozo L, Khoury S, Wein A. 2002, Plymouth, United Kingdom: Plymbridge Distributors Ltd, 85-163. 2
Igawa Y, Mattianson A, Andersson K-E: Functional importance of cholinergic and purinergic neuro-transmission for micturition contraction in the normal, unanesthetized rat. Br J Pharmacol. 1993, 109: 473-479.
Testa R, Angelico P, Velasco C, Guarneri L, Leonardi A: Urodynamic effects of oral oxybutynin in conscious rats under different cystometrographic conditions. 33rd International Continence Society Annual Meeting, Florence. 2003, Abs 316-
Maggi CA, Evangelista S, Grimaldi G, Santicioli P, Giolitti A, Meli A: Evidence for the involvement of arachidonic acid metabolites in spontaneous and drug-induced contractions of rat urinary bladder. J Pharmacol Exp Ther. 1984, 230: 500-513.
Maggi CA, Santicioli P, Furio M, Meli A: The effect of cyclooxygenase inhibitors on the low filling rate cystometrogram in urethane anesthetized rats. J Urol. 1985, 134: 800-803.
Maggi CA, Giuliani S, Patacchini R, Conte B, Furio M, Santicioli P, Meli P, Gragnani L, Meli A: The effect of SC-19220, a prostaglandin antagonist, on the micturition reflex in rats. Eur J Pharmacol. 1988, 152: 273-279. 10.1016/0014-2999(88)90722-4.
Maggi CA: Prostanoids as local modulators of reflex micturition. Pharmacol Res. 1992, 25: 13-20. 10.1016/S1043-6618(05)80059-3.
Yaksh TL, Durant PAC, Brent CR: Micturition in rats: a chronic model for study of bladder function on effect of anesthetics. Am J Physiol. 1986, 251: R1177-R1185.
Morikawa K, Hichihashi M, Kakiuchi M, Yamauchi T, Kato H, Ito Y, Gomi Y: Effects of various drugs on bladder function in conscious rats. Jpn J Pharmacol. 1989, 50 (4): 369-376.
Ferguson DR, Kennedy I, Burton TJ: ATP is released from rabbit urinary bladder epithelial cells by hydrostatic pressure changes – a possible sensory mechanism?. J Physiol. 1997, 505: 503-511. 10.1111/j.1469-7793.1997.503bb.x.
Pandita RK, Andersson K-E: Intravesical adenosine triphosphate stimulates the micturition reflex in awake, freely moving rats. J Urol. 2002, 168: 1230-1234. 10.1097/00005392-200209000-00094.
Cova R, Guarneri L, Angelico P, Velasco C, Leonardi A, Testa R: Effects of infravescical suramin and PPADS on cystometrographic parameters in conscious rats. Urodinamica. 1999, 9: 162-168.
Fabiyi AC, Gopalakrishnan M, Lynch JJ, Brioni JD, Coghlan MJ, Brune ME: In vivo evaluation of the potency and bladder-vascular selectivity of the ATP-sensitive potassium channel opener (-)-cromakalim, ZD6169 and WAY-133537 in rats. BJU Int. 2003, 91: 284-290. 10.1046/j.1464-410X.2003.03069.x.
Andersson K-E: Potential benefits of muscarinic M3 receptor selectivity. Eur Urol. 2002, 23-28. Suppl 1
Masuda H, Tsujii T, Azuma H, Oshima H: Role of a central muscarinic cholinergic pathway for relaxation of the proximal urethra during the voiding phase in rats. J Urol. 2001, 165: 999-1003. 10.1097/00005392-200103000-00076.
Yokoyama O, Ootsuka N, Komatsu K, Kodama K, Yotsuyanagi S, Niikura S, Nagasaka Y, Nakada Y, Kanie S, Namiki M: Forebrain muscarinic control of micturition reflex in rats. Neuropharmacol. 2001, 41: 629-638. 10.1016/S0028-3908(01)00102-2.
Ogasawara M, Shimoda N, Sato K, Kato T, Sugaya K: The effects of the antagonists of muscarinic acethylcholine receptor subtypes in rat brain on urinary bladder contraction. Nippon Hinyokika Gakki Zasshi. 2002, 93 (3): 427-434.
Ishiura Y, Yoshiyama M, Yokoyama O, Namiki M, De Groat WC: Central muscarinic mechanism regulating voiding in rats. J Pharmacol Exp Ther. 2001, 297: 933-939.
Andersson K-E, Yoshida M: Antimuscarinics and the overactive detrusor-which is the main mechanism of action ?. Eur Urol. 2003, 43: 1-5. 10.1016/S0302-2838(02)00540-7.
Kim Y, Yoshimura N, Masuda H, de Miguel F, Chancellor MB: Antimuscarinic agents exhibit local inhibitory effects on muscarinic receptors in bladder-afferent pathways. Urology. 2005, 65: 238-242. 10.1016/j.urology.2004.11.021.
Kawabe K, Abe S, Kanda T, Tei K: Clinical reevaluation of the effect of oxybutynin chloride on unhinibited neurogenic and reflex neurogenic bladder. Urol Int. 1986, 41: 16-20.
Stahl MMS, Ekstrom B, Sparf B, Mattiasson A, Andersson K-E: Urodynamic and other effects of tolterodine: a novel antimuscarinic drug for the treatment of detrusor overactivity. Neurourol Urodyn. 1995, 14: 647-655.